Fusion Antibodies – trading update estimates “cash runway has been maintained”. Has it really though?!…
By Steve Moore | Thursday 9 November 2023
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
Previously writing on antibody contract research organisation Fusion Antibodies (FAB), in August with the shares down to 6.625p I concluded they were a trading concerns avoid. A “half year trading update” announcement from the company now includes that it “has achieved a marked growth in the sales pipeline with overall values now standing at approximately four times that of six months ago”, but what of the shares currently materially further lower at below 4p in response?
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism
Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.